TRANSFUSION—VOLUME 31 (1991)
Subject Index

In the subject index, the page number refers to the first page of the communication in which the subject is addressed rather than to the specific page on which the referenced key words can be found. An "L" in parentheses following the page number indicates that the subject entry appeared in a letter to the editor; an "E" in parentheses indicates that the subject was discussed in an editorial.

In Volume 31 (1991), Number One (January) contains pages 1-95; Number Two (February), pages 96-191; Number Three (March-April), pages 192-287; Number Four (May), pages 288-382; Number Five (June), pages 383-478; Number Six (July-August), pages 479-576; Number Seven (September), pages 577-680; Number Eight (October), pages 681-785; Number Nine (November-December), pages 786- 890.

A

AABB, see American Association of Blood Banks
ABO blood group system ..... 77, 192(E), 197, 341, 577(E), 607, 631
Abstracts from the XIX International Congress of the World Federation of Hemophilia ..... 298(E), 372
Accounting, in establishing blood component costs ..... 293(E), 318
Acquired immune deficiency syndrome (AIDS)
  donor questions regarding
    risk behavior ..... 390(E), 466, 684, 698, 704
  education ..... 390(E), 466, 684, 698, 704
  risk factors in 704
Administration
  and blood component costs ..... 293(E)
  role in
    expansion of apheresis program 538
    reducing antibody-identification errors ..... 290(E), 313
Administrative Think Tank 450
Admixture blood warming 558
Adult T-cell leukemia/lymphoma 67
Age, limit for blood donation ..... 681(E), 686, 693
Agglutination, correlation with Ig class ..... 577(E), 607
AIDS, see acquired immune deficiency syndrome
Alanine aminotransferase (ALT)
  comparison of methods 527
  correlation with anti-HCV ..... 88(L), 109, 201, 443, 475(L), 771, 771, 780(L)
  donor deferral 201
  in determination of PTH ..... 88(L), 299
  microtiter plate assay 527
  predonation testing 201
Albumin
  effect on photosensitizers 415
  use in pediatric patients 52
Alloimmunization
  in Chinese patients 595
  prevention of ..... 584(E), 588, 595
  reduction by UVB irradiation 491
Aluminum phthalocyanine derivatives, in virus inactivation 102
ß-tocopheral ..... 476(L)
ALT, see alanine aminotransferase
Amegakaryocytic thrombocytopenia, use of tranexamic acid 345
American Association of Blood Banks
  managerial think tank report 450
  standards
    age limits for blood donors ..... 681(E), , 686, 693
    antibody detection in neonatal serum 631
    compatibility testing ..... 192(E), 197
    paternity testing ..... 383(E), 441
    Rh testing in donors and patients ..... 270, 273, 677(L)
    storage of frozen RBCs 648
    travel to or residence in malarious areas ..... 786(E),798
American trypanosomiasis, see Chagas' disease
Amphotericin B 392
AMT, aminomethyl trimethyl psoralen, see psoralen
Anemia
  hemolytic
    autoimmune 236
    due to Ceftriaxone (Rocephin) 176
  iron deficiency, from blood donation ..... 681(E), 684
Anesthesia and RBC transfusion in Cesarean delivery 12
Animal testing of blood substitutes 324, 369
Announcements 587
Anti-HBsAg, see hepatitis B surface antigen antibody
Anti-HCV, see hepatitis C antibody
Antibody-dependent, cell-mediated cytotoxicity assay 257
Antibody, general
  ABO ..... 77, 192(E), 197, 341, 577(E), 607, 631
  adsorption by platelets ..... 286(L)
  assessment of clinical significance 257
  autoantibody
    mimicking alloantibody 254
    in healthy population ..... 577(E), 607
  captopril-enhanced binding of platelet antibodies 752
  clonal distribution of RBC autoantibodies 236
  computer-assisted identification of ..... 290(E), 313
  detection of ABO incompatibility ..... 192(E), 197
  detection by flow cytometry 341
  donor-origin in solid-organ transplantation 77
  errors in identification of ..... 290(E), 313
  Ig class of ..... 577(E), 607
  IgG subclass of ..... 577(E), 607
  monoclonal detection of
    partial D antigens in Japanese donors ..... 782(L)
    Tn red cells 142
  prevalence in solid-organ transplantation 77
  radiographic contrast medium and 843
  subclass determination of ABO antibodies ..... 577(E), 607
Antibody, specific
  anti-Cr^a ..... 286(L), 782(L)
  anti-D ..... 288(E), 303, 380(L)
  anti-Do^a ..... 477(L)
  anti-Er^a ..... 572(L)
  anti-Ge 257
  anti-HPA-1a, see anti-PI^{A1}

"hr^B-like" 254
Kell system 77
anti-P ..... 190(L)
anti-P1^{A1}(anti-HPA-1a) ..... 189(L), 341, 752
Rh system 77
anti-Rh32 63
anti-Wr^a ..... 381(L), 783(L)
auto-anti-M 756
Antigen, general
association of i phenotype and congenital cataracts ..... 676(L)
detection after photoinactivation of viruses 636
effect of PKH-2 labeling 507
enzyme techniques, in typing for Do^a ..... 477(L)
enzymatic conversion of ..... 577(E)
HLA antigen, typing methods 846
incomplete expression of in neonatal patients 631
quantitiation of Rg/Ch antigens on red cells 222
receptor for *Mycoplasma pneumoniae* 627
sialoantigens 627
Antigen, specific
ABO ..... 192(E), 197, 341
Ch 222
Cr^a ..... 286(L), 782(L)
D ..... 188(L), 270, 273, 288(E), 303, 677(L)
Do^a ..... 477(L)
D^a ..... 270, 273, 288(E), 677(L)
D^{VI} 270
Er^a ..... 572(L)
I ..... 627, 676(L)
i ..... 676(L)
partial D ..... 782(L)
P1^{A1} (HPA-1a) 752
Rg 222
rh$_1$ 63
Rh33 759
Tn 142
Wr^a ..... 47, 381, 783(L)
Antiglobulin test, indirect, elimination of ..... 382(L)
Apheresis
donors, as bone marrow donors 138
therapuetic
CFU-GM in 327
cost of program expansion 538
in sickle cell disease and pregnancy 59
physiologic changes in 59
reactions during 335
selective removal of rheumatoid factor in rheumatoid arthritis ..... 96(E), 122
treatment of HDN ..... 380(L)
Assay
ALT 527
Chagas' disease ..... 479(E), 547, 814
CMV 245
FMH, detection of ..... 288(E), 303
HCV ..... 109, 616, 771, 777, 780(L), 781(L)
HIV antibody
EIA ..... 129, 388(E), 397
IFA 129
kit composition, variation, and sensitivity 388(E), 397
nef antibody 205
PCR 205
RIBA 129
Western blot 129, 205
HTLV-I/II 731
flow cytometry in
quantitation of WBCs in WBC-reduced components ..... 789(E), , 829, 835
RBC survival studies 507
immune function, red cell-monocyte assay and 218
paternity testing ..... 383(E), 441
platelet antibodies 341, 595
RBC
antibodies
antibody-dependent, cell-mediated cytotoxicity 257
IEF 236
monocyte monolayer 257
survival 507
Trypanosoma cruzi, antibody ..... 479(E), 547, 814
WBC quantitation in WBC-reduced components ..... 150, 156, 428, 433, 789(E), 792, 829, 835
Author's information
detailed 90
letters to the editor 89
Autologous
donations
preoperative
and immune modulation ..... 195(E), 212
appropriate transfusion of ..... 677(L)
disposition of units positive for infectious markers ..... 99(E)
indications for ..... 99(E), 481(E), 509, 677(L)
crossover of ..... 99(E), 616
measuring success of program ..... 481(E), 509
reasons for nondonation by surgical patients 810
safety of in nonhospital setting 513
survey of attitudes of donor room personnel 249
donors
crossover of blood from ..... 99(E), 616
erythropoietin levels in 650
iron stores in 650
reactions in ..... 285(L), 513
return as homologous donors 119
screening, HCV antibody 616
transfusion
and infection, versus homologous transfusion .. 195(E), 212
from large-volume bone marrow harvest ..... 191(L)
IBS and 662
risk of ..... 172, 676(L), 677(L)
risk of PTH, versus homologous tranfusion 299

B

Babesia divergens ..... 296(E), 365
Babesia microti ..... 296(E), 365
Babesiosis, transfusion-transmitted ..... 296(E), 365, 479(E)
Bacteria
contamination of bone marrow 521
physiology and growth of ..... 581(E), 620
transmission in tissue transplantation 277
Bag, lock box system ..... 386(E), 401
B_2-microglobulin and HIV serostatus 205
Baumgartner perfusion technique 308
Bentley apparatus, in IBS 662
Blood centers, revenue and costs ..... 293(E)
Blood components, establishing cost of ..... 293(E), 318
Blood group systems
ABO ..... 77, 192(E),197, 341, 577(E), 607, 631
Ch/Rg 222
classification of
Er^a ..... 572(L)
Wr^a ..... 47, 381(L)
Cromer ..... 286(L), 782(L)
Dombrock ..... 477(L)
Gerbich 257
Kell 77, 805
MNSs 756
P ..... 190(l)
Rh ..... 63, 77, 188(L), 254, 270, 273, 288(E), 303, 380(L), 677(L), 759, 782(L)
Blood group serology, RFLPs in 762
Blood services, establishing cost of ..... 293(E)
Blood substitutes 324, 369, 642
Blood supply, effect of reduction in shelf-life in RBCs and whole blood 464
Blood utilization review 355, 600

Blood warming and warmers 558
Bone marrow
transplantation
bacterial contamination of marrow 521
large-volume harvest and autologous transfusion .... 191(L)
mononuclear cell-enriched 724
reaction to cryopreserved marrow 521
recruitment of donors 138
second collections in 819
Bone transplantation, transmission of infection 277
Book review 360, 890
Books received 344, 414
BTHC, see butyryl-n-trihexyl-citrate
Butyryl-n-trihexyl-citrate (BTHC) 26

C

Calendar page ..... 587(E)
Cancer, effect of transfusion 114, 713
Captopril, enhanced binding of platelet antibodies 752
Cataracts, congenital and i phenotype ..... 676(L)
CCI, see corrected count increment
Ceftriaxone (Rocephin), association with hemolysis 176
Cell separators
bone marrow processing 724
collection of
apheresis platelets 335
PBSC 327
evaluation of 335
in IBS 662
Centrifuge braking speeds in preparation of
WBC-reduced platelets 743
Cesarean delivery, use of RBCs 12
CFU-GM, see colony-forming units—granulocyte macrophage
Chagas' disease ..... 479(E), 547, 814
Classical complement pathway 222
Clinical studies, retrospective ..... 195(E), 212
Cluster differentiation loci 829
CMV, see cytomegalovirus
Coagulation
in IBS 662
inhibitors of factor concentrates 265
Coagulopathy, mild, effect on bleeding 164
Cold agglutinin
and *Mycoplasma pneumoniae* 627
blood warming and 558
role in disease 361
Cold hemagglutin disease, differentiation from PCH ..... 190(L)
Collagen hemostatic material and use of IBS 662
Colony-forming units–granulocyte macrophage, (CFU-GM) in
apheresis 327
Compatibility testing
and computers ..... 192(E)
antiglobulin test, indirect, elimination of ..... 382(L)
immediate-spin
effect of delayed centrifugation 197
effect of delayed reading 197
electronic methods of ..... 192(E)
use of EDTA-suspended RBCs in 197
Complement
activation by Fluosol 642
auto-anti-M, activation of 756
binding to RBCs of C4 222
effect in compatibility testing 197
enumeration of C4, on RBCs 222
Computers
and compatibility testing ..... 192(E)
use in
antibody identification ..... 290(E), 313
assessment of appropriateness of platelet
transfusion 600
blood services operations 450
education of medical technologists ..... 290(E), 313
TRANSFUSION ..... 587(E)
utilization reviews 600
Confidence intervals in counting WBCs in WBC-reduced
components ..... 428, 789(E)
Confidential unit exclusion (CUE) ..... 4, 466, 704, 869(L), 870(L)
Corrected count increment (CCI) 392, 588
Correction
TRANSFUSION 1991;31;30-1 317
TRANSFUSION 1991;31:99-101 317
TRANSFUSION 1991;31:192-4 396
TRANSFUSION 1991;31:443-9 594
Cost accounting methods 318
Cost effectiveness of IBS 662
Costs
in expansion of apheresis program 538
in transfusion services ..... 293(E)
of blood services operations 450
of RBCs and whole blood 318
Countercurrent blood warmer 558
^{51}Cr, RBC survival studies, comparison with PKH-2 507
Creatinine, effect on postoperative bleeding 164
Creutzfeldt-Jakob disease, transmission in tissue
transplantation 227
Criteria maps, use in transfusion of pediatric patients 52
Cromer blood group system ..... 286(L), 782(L)
Cryoglobulin, as erythroid stem cell suppressant 361
Cryoprecipitate, thawed, stability of fibrinogen in 30
Cryopreservation
of platelets 160
reactions to cryopreserved bone marrow 521
Crystal violet ..... 479(E), 547
CUE, see confidential unit exclusion
Cytomegalovirus (CMV)
antibody detection, comparison of assays 245

D

Deglycerolization, role in transfusion reaction ..... 172, 676(L)
Demographics, donor ..... 450, 466, 479(E), 547, 681(E), 686,
693, 704, 719, 786(E), 798, 814
Detailed instructions for authors 90
DHE, see dihematoporphyrin ether
Diagnosis-related groups (DRGs)
transfusion practice and 355, 531
Dialyzable leukocyte extract 218
DIC, see disseminated intravascular coagulation
Dihematoporphyrin ether (DHE) 636
Dimethyl sulfoxide (DMSO) 521
Disaster and blood donations 719
Disease coding systems 531
Disseminated intravascular coagulation (DIC) 392
DNA, use in postmortem paternity testing ..... 383(E), 441
Dombrock blood group system ..... 477(L)
DMSO, see dimethyl sulfoxide
Donath-Landsteiner
antibody 756
test, detection of PCH ..... 190(L)
Donor
age limits for ..... 681(E), 686, 693
autologous
preoperative
attitude of donor room personnel toward 249
crossover of units ..... 99(E), 616
enrollment in program ..... 481(E), 509
immune modulation in ..... 195(E), 212
issues in ..... 99(E), 677(L)
reactions in ..... 285(L), 513
reasons for nondonation by surgical patients 810
return as homologous donors 119
screening, HCV antibody 616
safety of 249, 513
bone marrow 139, 819
deferral

ACT 201
CUE ..... 4, 466, 704, 869(L), 870(L)
education efforts ..... 4, 390(E), 466, 684(E), 698, 704
HCV antibody and ..... 780(L)
self-exclusion ..... 4, 390(E), 466
demographics ..... 450, 466, 479(E), 547, 681(E), 686, 693, 719, 786(E), 798, 814
directed
by HIV-1-infected donors 704
education and reduced number of 518
infectious disease markers in, Atlanta region ..... 872(L)
risk of GVHD 260
education 704
elderly ..... 681(E), 686, 693
epidemiology of HIV-1-infected donors 698
family member, risk of GVHD 260
high-risk behavior ..... 390(E), 466, 684(E), 698, 704
HIV-1-infected 704
iron levels, in elderly ..... 681(E), 686, 693
notification of HCV test results ..... 771, 780(L)
perception of risk for HIV infection 704
physiology, during hemodilution 856
plasma, for FVIII concentrate preparation ..... 573(L), 574(L)
reactions
comparison between groups of ..... 285(L)
during apheresis 335
in autologous donors ..... 285(L), 513
in elderly donors ..... 681(E), 686, 693
recruitment
as bone marrow donors 138
autologous donors as homologous 119
of surgical patients for autologous donation 810
strategy ..... 684(E), , 698, 704
response to disaster 719
room personnel, attitude toward 249
safety during
apheresis 335
phlebotomy ..... 681(E), 686, 693
screening
AIDS risk behaviors, questions for ..... 390(E), 466, 684(E), 698, 704
ALT ..... 88(L), 109, 201, 443, 475(L), 693, 719, 771, 780(L), 872(L)
anti-HBc .... 88(L), 109, 443, 693, 719, 771, 780(L), 872(L)
Babesia antibody ..... 296(E), 365
Chagas' disease ..... 479(E), 547, 814
CMV 245
CUE and ..... 466, 704, 869(L), 870(L)
Hepatitis B ..... 719, 771, 872(L)
HCV antibody ..... 88(L), 109, 201, 443, 475(L), 693, 719, 771, 777, 780(L), 781(L), 872(L)
HIV-1
AIDS risk behaviors, questions for ..... 390(E), 466, 684(E), 698, 704
antibody ..... 4, 693, 684(E), 698, 704, 719, 872(L)
assay comparisons ..... 129, 388(E), 397
IgA deficiency 633
HTLV-I ..... 379(L), 719
malaria ..... 786(E), 798
medical history questionnaire ..... 349, 684(E), 698, 704
NANBH 443
Rh blood group typing ..... 270, 273, 677(L)
syphilis 693, 719
Trypanosoma cruzi antibody 814
Yersinia enterocolitica 500
supplementation of
iron 686
with vitamin E ..... 476(L)
tissue, screening of 277
DRGs, see diagnosis-related groups
Drug-induced hemolytic anemia
Ceftriaxone (Rocephin) 176
radiographic contrast medium and 843
Dry-heat blood warmer 558
D^a testing
controversy of ..... 270, 273, 677(L)
determination of FMH ..... 288(E), 303

E

ECMO, see extracorporeal membrane oxygenation
Economic impact of recombinant FVIII ..... 573(L), 574(L)
Education
in donor exclusion ..... 4, 390(E), 466, 684(E), 698, 704
in use of preoperative autologous donations ..... 481(E), 509
of
donors about HIV risk factors ..... 684(E), 698, 704
donor room personnel about autologous transfusion 249
medical technologists ..... 290(E), 313
patients about directed donations 518
philosophy of ..... 290(E)
EIA, see enzyme immunoassay
Electromagnetic blood warmer 558
Enzyme kinetics, use in ALT testing 527
Enzyme immunoassay (EIA)
HIV antibody ..... 129, 388(E), 397
Er^a, genetic classification of ..... 572(L)
Errors, reduction of in antibody identification ..... 290(E), 313
Erythroid stem cell suppression, role of cryoglobulin 361
Erythropoietin levels, in autologous donors 650
Expert System for Platelet Request Evaluation 600
Extracorporeal membrane oxygenation (ECMO) ..... 478(L)

F

Factor VIII (FVIII)
concentrate
effect of gamma radiation 32
manufacture of ..... 573(L), 574(L), 871(L)
virus inactivation of 32
inhibitors 265
Fetomaternal hemorrhage (FMH)
detection of, comparison of methods for ..... 288(E), 303
incidence of ..... 188(L), 288(E)
FIAX, see fluorescence immunoassay
Fibrin, role in hemostasis 308
Fibrinogen, stability in thawed cryoprecipitate 30
Filters
WBC-reduction
comparison of ..... 40, 333, 433, 542, 789(E), 792, 829, 835
mechanisms of removal ..... 40, 581(E), 588, 620
FFP, see fresh-frozen plasma
Flow cytometry
detection of
FMH ..... 288(E), 303
platelet antibodies 341
in RBC survival studies 507
Fluorescence immunoassay (FIAX) 245
Fluosol, complement activation by 642
FMH, see fetomaternal hemorrhage
Freezing of
platelets 160
RBCs and storage limit 648
Fresh-frozen plasma (FFP)
use in
central Virginia 355
ECMO ..... 478(L)
paracentesis and thoracentesis 164
FVIII, see factor VIII concentrate

G

Gamma-interferon production 737
Gamma radiation, use in virus inactivation 32
Gastrointestinal illness, in screening donors for *Yersinia enterocolitica* 500

Genes
blood group, RFLPs in ... 762
D— ... 188(L)
Gerbich blood group system ... 257
Glycoprotein Ib, expression after UVB irradiation ... 491
Governance, of blood services ... 450
Graft-versus-host disease (GVHD) ... 260, 829
Granulocyte membrane protein-140 (GMP-140) ... 409
GVHD, see graft-versus-host disease

H

Hairy cell leukemia ... 731
HBsAg, see hepatitis B surface antigen
HBV, see hepatitis B virus
HCV, see hepatitis C virus
HDN, see hemolytic disease of the newborn
Hemodilution ... 856
Hemoglobin-based oxygen carriers ... 369
Hemolysis
immune
auto-anti-M in ... 756
autoimmune ... 236
due to Ceftriaxone (Rocephin) ... 176
differentiation from PCH ... 190(L)
in Kawasaki disease ... 572(L)
radiographic contrast media and ... 843
in frozen and washed RBCs ... 172, 676(L)
in solid-organ transplants from RBC antibodies ... 77
Hemolytic disease of the newborn (HDN)
anti-Rh32 and ... 63
anti-Wr^a and ... 381(L), 783(L)
detection of ... 288(E), 303
role of IgG subclass in ... 577(E), 607
treatment of ... 380(L)
Hemophilia, risk of HIV in ... 205
Hemostasis
maintenance in EMCO ... 478(L)
platelet subendothelial interaction in ... 308
role of
fibrin ... 308
tranexamic acid ... 345
Hepatitis
non-A,non-B
prevalence in Japanese blood donors ... 88(L)
relationship to
anti-HBc ... 443
HCV antibody ... 616
posttransfusion ... 87(L), 88(L), 299, 780(L), 872(L)
Hepatitis A virus ... 681(E)
Hepatitis B virus (HBV)
antibody to hepatitis B surface
antigen (anti-HBsAg), correlation with ALT ... 201
core antibody (anti-HBc)
correlation with ALT ... 201
prevalence in Japanese blood donors ... 88(L)
Hepatitis C virus (HCV)
antibody (anti-HCV)
assay comparison ... 616, 771, 777, 780(L)
borderline reactivity ... 781(L)
correlation with
ALT ... 88(L), 109, 201, 443, 475(L), 771, 777, 780(L)
anti-HBc ... 88(L), 109, 443
intrafamilial spread ... 475(L)
look-back for87(L), 88(L), ... 655
prevalence in
Amsterdam blood donors ... 777
Japanese blood donors ... 88(L)
route of transmission ... 777
Herpes virus 6, human ... 872(L)
Hip total replacement, use of RBCs in ... 531
Histocompatibility ... 846
HIV, see human immunodeficiency virus
HLA antibodies
adsorption of anti-Cr^a ... 268(L)
alloimmunization, reduction by
platelet crossmatching in Chinese patients ... 595
UVB irradiation ... 491
WBC reduction ... 584(E), 588, 595
detection by flow cytometry ... 341
grade and CCI ... 392
homozygosity and GVHD ... 260
removal of ... 286(L)
HLA antigens
Class I ... 846
Class II ... 846
serologic typing methods for ... 846
Homologous blood transfusion, risk of PTH ... 299
HTLV-I, see human T-lymphotropic virus type I
HTLV-II, see human T-lymphotropic virus type II
HTLV-I-associated myelopathy (HAM) ... 67, 379(L)
Human immunodeficiency virus type 1 (HIV-1)
antibody
comparison of assays ... 129, 205, 397
kit composition, sensitivity, variability 388(E), 397
-positive blood donors ... 684(E), 698, 704
prevalence in donors ... 4
relationship to anti-HBc ... 443
education about AIDS
risk behaviors ... 390(E), 466, 684(E), 698, 704
look-back for ... 4, 655
inactivation by
DHE ... 636
gamma radiation ... 32
-infected blood donors ... 684(E), 698, 704
risk
before 1985 ... 4
factors in ... 684, 698, 704
in seronegative at-risk individuals ... 205
of transmission in tissue transplantation ... 277
routes of transmission ... 698
seroconversion, appearance of antibody classes 388(E), 397
Human T-lymphotropic virus type I (HTLV-I)
donor screening ... 379(L), 719
epidemiology of ... 67
look-back ... 655
serologic distinction between HTLV-II ... 731
virus structure and composition ... 67
Human T-lymphotropic virus type II (HTLV-II) ... 731
Human studies of blood substitutes ... 369
Hypothermia ... 558
Hypoxanthine ... 379(L)

I

IAT, see intraoperative autologous transfusion
IBS, see intraoperative blood salvage
Identification, of patient ... 386(E), 401
Identification systems, in transfusions ... 386(E), 401
IEF, see isoelectric focusing
IFA, see indirect immunofluorescence assay
Immune globulins
IgA, deficiency ... 633
IgG
antibody appearance in HIV infection ... 388(E), 397
antibody to A and B blood group substances ... 577(E), 607
removal by immunoadsorption ... 265
subclass, in antibodies to A
and B blood group substances ... 577(E), 607
IgM
antibody appearance in HIV infection ... 388(E), 397
antibody to A and B blood group substances ... 577(E), 607
increases after blood transfusion ... 713
Immune hemolytic anemia, due to Ceftriaxone (Rocephin) ... 176
Immune modulation
and transfusion ... 114, 195(E), 212, 710, 713

by dialyzable leukocyte extract ... 218
in autologous donations ... 195(E), 212
Immune response
and dialyzable leukocyte extract ... 218
of neonatal patients to transfusion ... 737
role of T-cell ... 180
Immunoadsorption of inhibitors to coagulation factors ... 265
Indirect immunofluoresence assay (IFA)
HIV, antibody ... 129
platelet antibody detection ... 341
Infection
postoperative, effect of transfusion ... 114, 710, 713
tissue-transmitted ... 277
transfusion effect ... 195(E), 212
Information systems, use in blood services operations ... 450
Informed consent, in HCV look-back ... 87(L)
Inhibitors, to coagulation factors, removal by extracorporeal immunoadsorption ... 265
Instructions for authors
detailed ... 90
letters to the editor ... 89
Interleukin-2 ... 713
International Congress of the World Federation of Hemophilia, abstracts of ... 298(E), 372
International Histocompatibility Workshops ... 846
Intraoperative autologous transfusion (IAT) ... 481(E), 509
Intraoperative blood salvage (IBS) ... 662
Intravenous drug abusers, risk of HIV ... 698
Intravenous immune globulin (IVIG) ... 380(L), 423
Iron stores, in blood donors ... 650, 681(E), 686, 693
Irradiation
prevention of GVHD ... 260, 497
RBC storage lesion ... 497
Isoelectric focusing (IEF), pattern of RBC antibodies in AHA ... 236
Ixodes dammini ... 296(E), 365
IVIG, see intravenous immune globulin

K

Kawasaki disease ... 572(L)
Kell blood group system ... 77, 805
Knee total replacement, use of RBCs in ... 531

L

Labor
effect on blood services operations ... 450
cost in apheresis expansion program ... 538
Legislation, in blood services operations ... 450
Letters to the Editor, instructions ... 89
Liability, in blood services operations ... 450
Litigation, in blood services operations ... 450
Look-back
HCV ... 87(L), 88(L), 655
HIV ... 4, 655
HTLV ... 655
routine posttransfusion follow-up ... 87(L)
Lymphocyte
activation, in response to transfusion ... 737
subset analysis in
neonatal patients after transfusion ... 737
WBC-reduced components ... 433, 829
Lymphokines ... 713

M

Malignancy and use of IBS ... 662
Malaria ... 789, 798
Management of blood service centers ... 450
Marginal costs, in expansion of apheresis program ... 538
McLeod phenotype ... 805
Medical history questionnaire, standardization of ... 349
Medical technologists, education of ... 290(E), 313
Merocyanine 540 ... 415, 483
Microtiter plate assay for ALT ... 527
Microwave oven blood warmers ... 558
Mission, of blood service centers ... 450
MNSs blood group system ... 756
Monoclonal antibodies
detection of partial D antigens in Japanese donors ... 782(L)
in examination of Tn red cells ... 142
use in D^u testing ... 270, 273
Monocyte monolayer assay ... 257
Monocytes, effect of dialyzable leukocyte extract on ... 218
Mycoplasma pneumoniae ... 627

N

NANBH, see hepatitis, non-A,non-B
nef antibody ... 205
Neonatal patients
detection of circulating anti-A in ... 631
immune response to transfusion ... 737
transfusion practice
in ECMO ... 478(L)
safety of extended-storage RBCs in ... 229
volume-reduced platelets stored in syringes ... 404
Neopterin
and HIV status ... 205
production in response to transfusion ... 737
Nomenclature, in Rh typing ... 270, 273, 677(L)

P

P blood group system ... 190(L)
Panstrongylus megistus ... 547
Paracentesis, bleeding in ... 164
Parasitic infections, transfusion-transmitted ... 479(E), 547, 786(E), 798
Paroxysmal cold hemoglobinuria (PCH) ... 190(L)
Passive latex agglutination ... 245
Patient identification ... 386(E), 401
Paternity index ... 823
Paternity testing ... 188(L), 383(E), 441, 823
PBSC, see peripheral blood stem cells
PCH, see paroxysmal cold hemoglobinuria
PCR, see polymerase chain reaction
PEG, see polyethylene glycol
Pepsin and low pH in virus inactivation ... 423
Percoll, use in WBC reduction ... 433
Perfluorodecalin ... 324
Peripheral blood stem cell (PBSC), collection ... 327
Personnel, donor room, attitude toward autologous donors ... 249
Phagocytosis, bacterial ... 581(E), 620
Physiology, of donor during hemodilution ... 856
Photosensitization
by psoralen and UVA ... 483
comparison of methods ... 483
inhibition by albumin ... 415
merocyanine 540-mediated ... 415, 483
PKH-2, use in RBC survival studies ... 507
Plasma
as platelet storage media ... 1(E), 21
bactericidal effect ... 581(E), 620
effect of gamma radiation ... 32
in virus inactivation ... 483
revenue in expansion of apheresis program ... 538
transfusion
use in pediatric patients ... 52
virus inactivation in ... 32
Plasmodium falciparum
inactivation by DHE ... 636
-transfusion-transmitted ... 786(E),798
Plasmodium malariae ... 786(E),798
Plasmodium ovale ... 786(E), 798
Plasmodium vivax ... 786(E), 798
Plasticizers in blood bags, BTHC ... 26
Platelet
activation

during preparation ..... 1(E)
during storage 409
during storage in synthetic media 21
aggregation response after photosensitization 483
alloimmunization, prevention of ..... 491, 584(E), 588, 595
concentrate
CMV antibody in 245
preparation
braking speeds during centrifugation 743
comparison of methods 542, 743
WBC reduction during, by filter 542
preservation and storage
activation during ..... 1(E), 21, 409
after UVB irradiation 491
at 4 versus 22°C 308
effect of
merocyanine 540 ..... 415, 483
photosensitization 415, 483
expression of GMP-140 during 409
function
after
freezing 160
WBC reduction 333
during 21
in citrate-plasticized PVC bag 335
mean platelet volume in ..... 381(L)
membrane changes in 21
media
plasma ..... 1(E)
synthetic ..... 1(E), 16, 21
metabolism in ..... 1(E), 16, 21
morphology changes in ..... 21, 381(L)
platelet distribution width ..... 381(L)
sterility in ..... 1(E)
volume-reduced in syringes 404
WBC reduction in ..... 1(E), 333, 433, 542, 584(E), 588, 743
crossmatching, to reduce alloimmunization 595
distribution width ..... 381(L)
expression of A antigen on 341
function after transfusion 308
membrane changes
after UVB irradiation 491
during storage 409
morphology
after photosensitization 483
after UVB irradiation 491
photosensitization of 483
quality
after preservation and storage ..... 1(E)
subendothelial interaction in rabbit arterial segments 308
survival
after
activation 409
freezing 160
storage 409
storage in
citrate-plasticized PVC bags 335
synthetic media ..... 1(E), 16, 21
WBC reduction 333
transfusion
assessment of appropriateness of 600
CCI 392
use in
amegakaryocytic thrombocytopenia 345
central Virginia 355
pediatric patients 52
volume, mean ..... 381(L)
Points to consider, blood substitutes 369
Polyethylene glycol (PEG), use in detection of FMH ..... 288(E), 303
Polymerase chain reaction (PCR)
HCV testing ..... 780(L)
HIV serostatus 205
paternity testing ..... 383(E), 441
Polyvinylchloride (PVC), platelet storage bags 335
Posttransfusion hepatitis (PTH), see hepatitis
Posttransfusion purpura ..... 189(L), 752
Potassium leak, in gamma-irradiated RBCs ..... 476(L)
Precision in counting WBCs in WBC-reduced components ..... 428, 789(E) 829, 835
Pregnancy, and theraputic apheresis for sickle cell disease 59
Probability of paternity 823
Propidium iodide ..... 156, 789(E), 829, 835
Psoralen and UVA in photosensitization 483
PTH, see posttransfusion hepatitis
Public perception 450
PVC, see polyvinylchloride

Q

Quality control
in IBS 662
quantitation of WBCs in WBC-reduced components ..... 150, 156, 428, 789(E), 792, 829, 835

R

R^N, products of gene 63
Rabbit arterial segments 308
Rabies, transmission in tissue transplantation 277
Radiation
gamma, use in virus inactivation 32
Radiowave blood warmers 558
RBCs, see red cells
Reagents
in D^e testing 270, 273
monoclonal antibody detection of partial D ..... 782(L)
Recombinant FVIII ..... 573(L), 574(L)
Recombinant immunoblot assay (RIBA)
HCV 109
HIV 129
Recruitment
donor
bone marrow donors 138
autologous donors as homologous 119
Red cells (RBCs)
addition of crystal violet 547
additives, effect on neonatal patients 229
antibodies, IEF pattern in AHA 236
complement binding 222
estimating cost of 318
freezing and washing, reactions in ..... 172, 189(L), 676(L)
gamma radiation of ..... 476(L), 497
IgG-sensitized and dialyzable leukocyte extract 218
membrane changes during warming 558
membrane protein methylation in McLeod cell 805
outdate and transfusion date 464
photoinactivation of viruses, effect on 636
presence of Rg and Ch on 222
preservation and storage
after
10 years' frozen storage 648
gamma radiation ..... 476(L), 497
changes in
ATP 26
2,3 DPG 26
hypoxanthine in ..... 379(L)
metabolism during 26
outdate of 464
salvaged during IBS 662
survival
after
frozen storage 648
preparation with BTHC 26
and anti-Wr^a ..... 782(L)

assessment of clinical significance of antibody 257
comparison of labeling methods 507
flow cytometry in evaluation of 507
storage lesion 497
transfusion
and outdate of 464
use in
central Virginia 355
Cesarean delivery 12
hip surgery 531
knee surgery 531
neonatal patients 229
pediatric patients 52
virus inactivation effect on 102
warming 558
WBC-reduced ..... 40, 150, 156, 433, 497, 737, 789(E), 792, 829, 835
Regulatory issues 450
Restriction fragment length polymorphism (RFLP) in
blood group serology 762
paternity testing ..... 383(E), 441
Revenue, in transfusion services ..... 293(E)
RFLP, see restriction fragment length polymorphism
Rheumatoid arthritis ..... 96(E), 122
Rheumatoid factor ..... 96(E), 122
Rh blood group system ..... 63, 77, 188(L), 254, 270, 273, 288(E), 303, 380(L), 677(L), 759, 782(L)
Rh immune globulin (RHIG) ..... 288(E), 303
RhIG, see Rh immune globulin
Rhodnius pallenscens 547
Rhodnius prolixus 547
RIBA, see recombinant immunoblot assay
Risk/benefit
analysis of malaria standards ..... 786(E), 798
ratio 52
Risk management 450
Rocephin, see Ceftriaxone
Rosette test, detection of FMH ..... 288(E), 303

S

Safety of
autologous donation 249, 513
blood substitutes 324, 369, 642
blood donation by elderly ..... 681(E), 686, 693
extended-storage RBC transfusion in neonatal patients 229
blood supply ..... 390(E), 443, 466, 719
second collection of bone marrow 819
tissue transplants 277
transfusion ..... 386(E), 401
volume-reduced platelets stored in syringes 404
Sampling error, in counting WBCs
in WBC-reduced components ..... 428, 789(E), 829, 835
Semen, -transmitted diseases 277
Sensitivity, of quantification methods in
WBC-reduced components ..... 150, 156, 789(E), 792, 829, 835
Sickle cell disease, theraputic apheresis in pregnancy 59
Splenectomy, effect on CCI 392
Standards
detection of circulating anti-A in neonatal serum 631
donor medical history questionnaire 349
paternity testing ..... 383(E), 441
storage of frozen RBCs 648
travel to or residence in malarious areas ..... 786(E), 798
Storage lesion, RBCs 497
Submission requirements
detailed 90
letters to the editor 89
Substitutes, blood 324, 369, 642
Surgical blood order schedule ..... 382(L)
Survival, cancer and effect of blood transfusion 114, 713
Syringe storage of platelets 404

T

T cells 180
Technology, development for FVII production ..... 573(L), 574(L)
Terminology
blood group ..... 572(L)
use of -fold ..... 475(L)
Thawing, of red cells ..... 172, 676(L)
Think Tank, administrative 450
Thoracentesis, bleeding in 164
Thrombocytopenia after frozen-thawed red cell transfusion ..... 189(L)
amega Karyocytic 345
Tissue, -transmitted infections 277
Tranexamic acid 345
Transferases, *ABO* ..... 577(E), 607
TRANSFUSION
abbreviations list ..... 3(E)
announcements ..... 587(E)
calendar page ..... 587(E)
computerization of ..... 587(E)
mailing of ..... 3(E)
purchase of ..... 3(E)
use of SI units ..... 3(E)
Transfusion
and immune modulation ..... 114, 195(E), 212, 710, 713
and postoperative infection ..... 114, 195(E), 212, 710
autologous versus homologous ..... 195(E), 212, 299
-associated fatalities ..... 386(E), 401
complications
hypoxanthine in stored RBCs ..... 379(L)
postoperative bacterial infection ..... 195(E), 212
medicine
education
of medical technologists ..... 290(E), 313
philosophy of ..... 290(E)
use of components in pediatric patients 52
services, estimating cost of ..... 293(E), 318
practice
appropriate use of autologous blood ..... 677(L)
blood substitutes, complement activation by 642
blood warming 558
ECMO and ..... 478(L)
DRGs and 355, 531
hemodilution 856
in paracentesis and thoracentesis 164
individual components
albumin, in pediatric patients 52
FFP, in
central Virginia 355
ECMO ..... 478(L)
neonatal patients ..... 478(L)
paracentesis and thoracentesis 164
pediatric patients 52
fresh whole blood 260
platelets
assessment of appropriateness of 600
CCI, 20-hour 392
effect of tranexamic acid on 345
use in
central Virginia 355
neonatal patients 404
pediatric patients 52
red cells
autologous, risk of ..... 172, 299, 676(L)
neonatal patients 229
pediatric patients 52
salvaged in IBS 662
use in
central Virginia 355
Cesarean delivery 12
hip surgery 531
knee surgery 531

warming of ... 558
massive transfusion ... 558
neonatal patients
blood warming in ... 558
ECMO and ... 478(L)
use of
extended-storage RBCs ... 229
volume-reduced platelets stored in syringes ... 404
patient identification ... 386(E), 401
pediatric patients, evaluation of ... 52
use of
blood utilization review in ... 355
criteria maps in evaluation of ... 52
DRGs to determine potential blood loss ... 531
IBS ... 662
in second collection of bone marrow ... 819
preoperative autologous blood donation . 99(E), 677(L)
WBC-reduced components to prevent alloimmunization ... 584(E), 588, 594
reaction
and anti-Do^a ... 477(L)
during blood donation in elderly ... 681(E), 686, 693
GVHD ... 260, 829
in frozen and washed autologous RBCs ... 172, 676(L)
posttranfusion purpura after frozen-thawed red cells ... 189(L)
to cryopreserved marrow ... 521
reasons for nondonation of autologous blood
by surgical patients ... 810
services, estimating cost of ... 293(E), 318
-transmitted diseases
bacteria ... 195(E), 464, 581(E), 620
Babesiosis ... 296(E), 365, 479(E)
Chagas' disease ... 479(L), 547, 810
CMV ... 245
hepatitis A ... 681
hepatitis B ... 443
HCV ... 87(L), 88(L), 443, 616
hepatitis, posttransfusion ... 88(L), 443, 616
HIV-1 ... 4, 390(E), 466, 684, 698, 704
HTLV-I/II ... 67, 379(L)
malaria ... 786(E),798
NANBH ... 443, 616
Yersinia enterocolitica ... 464, 500
Transplantation
bone, transmitted infections ... 277
bone marrow
bacterial contamination of ... 521
cell separator processing ... 724
large-volume harvest and autologous transfusion ... 191(L)
reactions to cryopreserved marrow ... 521
role of 20-hour CCI in platelet transfusion ... 392
recruitment of donors for ... 138
second collection of ... 819
histocompatibility and ... 846
PBSC collection of ... 327
solid-organ, RBC antibodies in ... 77
tissue-transmitted diseases ... 277
TRAP, see Trial to Reduce Alloimmunization to Platelets
Tropical spastic paraparesis ... 67, 379(L)
Trial to Reduce Alloimmunization to Platelets (TRAP) ... 584(E), 588
Triatoma dimidiata ... 547
Triatoma infestans ... 547
Triatoma sordida ... 547
tri(N-butyl)phosphate in FVIII concentrates ... 871(L)
Trypanosoma cruzi ... 479(E), 547, 814
Trypsin, effect on C4d and C3d ... 222
Type and screen ... 382(L)

U

UVA, see ultraviolet A light
UVB, see ultraviolet B irradiation
Ultraviolet A light (UVA) ... 483
Ultraviolet B irradiation (UVB) ... 491
Ultraviolet irradiation, role in reduction of alloimmunization ... 584(E), 588, 595
Utilization review ... 600

V

Variable number tandem repeats (VNTR), in paternity testing ... 383(E),441
Virus
inactivation in blood components
albumin inhibition of ... 415
by aluminum phthalocyanine derivatives ... 102
by gamma radiation ... 32
DHE and ... 636
effect of plasma concentration on ... 483
in IVIG production ... 423
merocyanine 540 in ... 415, 483
oxygen levels in ... 483
psoralen and UVA in ... 483
red cell stability in ... 102
Vitamin E ... 476(L)
VNTR, see variable number tandem repeats
von Willebrand factor, inhibitors of ... 265

W

Warm autoimmune hemolytic anemia, differentiation from PCH ... 190(L)
Waterbath blood warmers ... 558
WB, see Western blot
WBCs, see white cells
Western blot (WB)
detection of
HIV ... 129, 205
HTLV-I/II ... 67
White cells (WBCs)
effect on
bacteria in stored RBCs ... 581(E), 620
platelets during storage ... 1(E)
sterility of platelet components ... 1(E)
-reduced components
effect on alloimmunization ... 584(E), 588, 595
mechanisms of removal ... 40
platelets ... 1(E), 333, 433, 542, 743
quantitation of WBCs in
and sampling errors in ... 428, 789(E), 829, 835
confidence intervals in ... 428, 789(E), 829,835
fluorescence analysis ... 150, 156, 789(E), 829, 835
modified cytospin ... 150
Nageotte hemocytometer ... 792
precision in ... 428, 789, 829, 835
red cells ... 40, 150, 156, 433, 497, 789, 829, 835
subset determination in WBC-reduced components ... 433, 829
timing of WBC reduction ... 581(E), 620
Whole blood
effect of virus inactivation on ... 102
estimating cost of ... 318
fresh and GVHD ... 260
outdate and transfusion date ... 464
World Federation of Hemophilia, abstracts from XIX International Congress ... 298(E), 372
Wr^a
genetics of ... 47
role in HDN ... 381(L), 783(L)

Y

Yersinia enterocolitica ... 464, 500, 581(E),620